GLP-1 Titration Calculator â€” Stop Guessing Your Dose

Step 01

Pick Your Compound

Each titration schedule is pulled directly from published clinical trial protocols.

Semaglutide

GLP-1 Agonist

Ozempic / Wegovy

Tirzepatide

Dual GIP/GLP-1

Mounjaro / Zepbound

Retatrutide

Triple Agonist

GIP/GLP-1/Glucagon

Mazdutide

Dual GLP-1/Glucagon

Investigational

Step 02

Your Protocol Variables

Current week, vial details for reconstitution, and optional cost tracking.

Current Week in Protocol

week

Vial Size (peptide amount)

BAC Water Volume

Cost Per Vial (optional)

Titration Schedule

Semaglutide Titration Protocol

Weekly subcutaneous injection. Current week highlighted.

Weeks	Dose / Week	Units to Inject	Volume (mL)	Side Effects

If side effects are intolerable at any tier, hold for 2 additional weeks before titrating up. Pushing through significant nausea or GI distress is not discipline. It is poor protocol management.

Reconstitution Results -- Current Dose

Concentration

2.50

mg/mL

Current Dose

0.25

mg/week

Units to Draw

on insulin syringe

Volume to Draw

0.10

Total Vials Needed

for full protocol

Estimated Total Cost

for full protocol

Draw to the 10 unit mark on a 100 unit (1 mL) insulin syringe

Protocol Timeline

Your Titration Map

Complete titration plan with expected side effects at each stage. Green dot marks your current tier.

Side Effect Management

Side Effects Are Manageable If You Know What to Expect

Dose-dependent and most pronounced during titration increases. Most attenuate within 1-2 weeks at a stable dose.

Nausea +

The most common side effect, affecting 20-44% of users depending on compound and dose. Peaks during dose escalation and typically resolves within 1-2 weeks at stable dose.

Eat smaller, more frequent meals
Avoid high-fat and greasy foods, especially around injection day
Ginger supplementation (250-500mg) or ginger tea
Eat slowly and stop before feeling full
Stay hydrated -- dehydration worsens nausea
If persistent beyond 2 weeks at a stable dose, hold titration

Constipation +

GLP-1 agonists slow gastric emptying, which can cause constipation in 10-24% of users. This is manageable with proactive strategies.

Increase fiber intake (25-35g/day minimum)
Drink at least 2.5-3L of water daily
Magnesium citrate (200-400mg before bed)
Psyllium husk supplementation
Regular physical activity promotes motility
If severe, consider polyethylene glycol (MiraLAX)

Injection Site Reactions +

Redness, swelling, or itching at the injection site. Typically mild and self-resolving.

Rotate injection sites (abdomen, thigh, upper arm)
Allow the solution to reach room temperature before injecting
Inject slowly over 5-10 seconds
Avoid injecting into areas with skin irritation or scarring
Clean the site with alcohol and let it dry before injection

Fatigue and Low Energy +

Reduced caloric intake combined with metabolic changes can cause fatigue, especially during the first 2-4 weeks. Usually transient.

Ensure adequate caloric intake -- do not crash diet on top of GLP-1 appetite suppression
Maintain electrolyte intake (sodium, potassium, magnesium)
Monitor for signs of hypoglycemia if diabetic or using other glucose-lowering agents
Adjust training intensity during initial titration if needed
If persistent beyond 4 weeks, re-evaluate dose

Muscle Loss Risk -- CRITICAL +

This is the primary concern for athletes and physique-focused individuals. STEP and SURMOUNT trial data show approximately 25-40% of total weight lost is lean mass. This is unacceptable for anyone who has built significant muscle.

Protein intake: 1g per pound of bodyweight minimum -- this is non-negotiable
1.2-1.5g/lb is preferable for enhanced athletes on GLP-1
Resistance training 3-5x per week is mandatory, not optional
Prioritize compound movements and progressive overload
Track body composition (DEXA or calipers), not just scale weight
Consider creatine monohydrate (5g/day) for muscle retention
Do not exceed a 500-750 calorie deficit -- the GLP-1 will handle appetite

Gallbladder Risk +

Rapid weight loss (>1.5kg/week sustained) increases the risk of gallstone formation and cholecystitis. This risk is compounded with higher GLP-1 doses.

Monitor for right upper quadrant abdominal pain, especially after eating
Avoid extremely rapid weight loss -- titrate dose to achieve 0.5-1.0kg/week loss
Do not skip meals entirely -- some dietary fat is needed for gallbladder function
Ursodeoxycholic acid (UDCA) may be considered prophylactically at higher doses
Report any acute upper abdominal pain radiating to the back immediately

If You Are Enhanced, Read This

Show

GLP-1 agonists interact with compounds commonly used by enhanced athletes. Know the interactions before you combine.

Synergy

GLP-1 + AAS (Anabolic-Androgenic Steroids)

Anabolic steroids provide a significant muscle-preservation advantage when running GLP-1 agonists. The primary risk of GLP-1 therapy -- lean mass loss -- is substantially mitigated by the anti-catabolic and anabolic effects of AAS. This is arguably the most effective combination for body recomposition. Protein intake of 1g/lb minimum remains mandatory.

Synergy

GLP-1 + HGH (Human Growth Hormone)

Complementary mechanisms for body composition. GLP-1 drives appetite suppression and improved insulin sensitivity. HGH promotes lipolysis and lean mass preservation through IGF-1 mediated pathways. Together they enhance fat loss while protecting muscle. HGH may also mitigate some of the fatigue associated with caloric restriction on GLP-1.

Caution

GLP-1 + MK-677 (Ibutamoren)

MK-677 increases appetite significantly through ghrelin receptor agonism -- this directly opposes the appetite suppression from GLP-1. The combination may partially cancel the appetite-reducing benefit. More critically, MK-677 can elevate fasting blood glucose and impair insulin sensitivity. When combined with GLP-1, monitor fasting glucose and HbA1c closely. If blood glucose rises above 100 mg/dL fasting, reconsider this combination.

Dangerous

GLP-1 + Exogenous Insulin

This combination carries serious hypoglycemia risk. GLP-1 agonists enhance endogenous insulin secretion in a glucose-dependent manner. Adding exogenous insulin on top creates unpredictable, potentially severe hypoglycemic events. This combination requires direct medical supervision and continuous glucose monitoring. Do not combine without physician oversight. Severe hypoglycemia can be fatal.

Monitor

GLP-1 + Metformin / Berberine

Additive blood sugar lowering effect. Both metformin and berberine reduce hepatic glucose output and improve insulin sensitivity. Combined with GLP-1, the glucose-lowering effect is amplified. While generally tolerable, monitor fasting glucose regularly. GI side effects (nausea, diarrhea) may be compounded -- berberine especially can worsen the GI effects of GLP-1. Start berberine at low doses and titrate separately from GLP-1 dose increases.

Protein Requirements -- Enhanced + GLP-1

1.0-1.5g protein per pound of bodyweight when enhanced AND on GLP-1. The caloric deficit induced by GLP-1 creates a catabolic environment. If you are enhanced, you have more muscle to lose. Protein synthesis rates are elevated on AAS, but substrate (amino acids) must be available. Skimping on protein while on GLP-1 will cost you muscle regardless of anabolic support.

Indicated Bloodwork Panel

Check before starting GLP-1 therapy and every 8 weeks during use.

HbA1c (glycated hemoglobin) Baseline + Q8W
Fasting Glucose Baseline + Q8W
Fasting Insulin Baseline + Q8W
Lipase Baseline + Q8W
Amylase Baseline + Q8W
Comprehensive Metabolic Panel (CMP) Baseline + Q8W
Thyroid Panel (if on retatrutide -- glucagon receptor agonism) Baseline + Q12W

Protocol Summary

Export Your Protocol

Plain-text summary with reconstitution details, vial counts, and timeline. Copy and keep it.

Disclaimer

Educational and research purposes only. Not medical advice. GLP-1 receptor agonists are prescription medications in most jurisdictions. Verify all dosing calculations independently. Research peptides are not approved for human use. Consult a qualified healthcare provider before starting any medication or peptide protocol. Persistent vomiting, severe abdominal pain, or signs of pancreatitis require immediate medical attention.